Take another look at the popular hypothesis that suggests type 2 diabetes has an acute effect on the secretion of GLP-1 and that lower GLP-1 secretion has an acute effect on insulin. It doesn't work that way, said Michael Nauck, MD, PhD, Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany. Decreased GLP-1 secretion is not part of the pathophysiology of type 2 diabetes.
Take another look at the popular hypothesis that suggests type 2 diabetes has an acute effect on the secretion of GLP-1 and that lower GLP-1 secretion has an acute effect on insulin. It doesn't work that way, said Michael Nauck, MD, PhD, Diabeteszentrum Bad Lauterberg, Bad Lauterberg, Germany. Decreased GLP-1 secretion is not part of the pathophysiology of type 2 diabetes.
"The majority of papers show very close to normal secretions of GLP-1 and GIP compared to controls," Dr. Nauck explained. "GLP-1 probably does not have a significant impact on insulin in the short term."
The key is timing, Dr. Nauck continued. Total GLP-1 secretion is reduced by about 53% in patients with type 2 diabetes. But the decrease in secretion compared to normal control subjects does not begin until about an hour after eating, either a mixed meal or oral glucose. The ramp up of GLP-1 secretion is nearly identical in diabetic patients and controls for the first 30 to 60 minutes after eating.
Four factors in GLP-1 secretion
More detailed analysis shows that GLP-1 secretion is dependent on four factors: age, body mass index (BMI), glucagon levels, and free fatty acids.
Increasing age and increasing levels of free fatty acids are both associated with increased levels of GLP-1. Higher BMI and higher glucagon levels are associated with decreased levels of GLP-1.
Patients with diabetes are typically older and heavier, with elevated glucagon and elevated free fatty acids, Dr. Nauck said. The different interaction among these four factors in each individual seems to control GLP-1 secretion.
"There is no general abnormality of GLP-1 secretion in type 2 diabetes," he said. It is the individual variation that makes the difference."
Multiple drugs can affect GLP-1 secretion, he added, including metformin, sitagliptin and voglibose. Trials with other agents are under way, including human GLP-1 analogs.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More